QS Investors’s iRadimed IRMD Stock Holding History

QS Investors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-300	Closed	-$7K	–	1360
2020 Q2	$7K	Hold	300	–	–	﹤0.01%	1584
2020 Q1	$7K	Hold	300	–	–	﹤0.01%	1560
2019 Q4	$8K	Buy	+300	New	+$7.01K	﹤0.01%	1551

Other funds holding IRMD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

RCMC

RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

QS Investors's IRMD Position: Q3 2020 in Review

QS Investors sold out of iRadimed (IRMD) in Q3 2020, closing a stake of 300 shares — an estimated $7K sold.

QS Investors first reported a position in IRMD in Q4 2019 and held it in 3 quarters. The position peaked at $8K in Q4 2019. 62 funds tracked by Wall St. Rank hold IRMD as of Q3 2020.

QS Investors reported no remaining iRadimed position as of Q3 2020 after selling out during the quarter.
QS Investors sold 300 iRadimed shares in Q3 2020, an estimated $7K.
QS Investors first reported a position in iRadimed in Q4 2019 and held it in 3 quarters.
QS Investors's iRadimed position peaked at $8K in Q4 2019.
62 funds tracked by Wall St. Rank held iRadimed as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.